BR112023021970A2 - Novas ergolinas e métodos de tratamento de transtornos de humor - Google Patents
Novas ergolinas e métodos de tratamento de transtornos de humorInfo
- Publication number
- BR112023021970A2 BR112023021970A2 BR112023021970A BR112023021970A BR112023021970A2 BR 112023021970 A2 BR112023021970 A2 BR 112023021970A2 BR 112023021970 A BR112023021970 A BR 112023021970A BR 112023021970 A BR112023021970 A BR 112023021970A BR 112023021970 A2 BR112023021970 A2 BR 112023021970A2
- Authority
- BR
- Brazil
- Prior art keywords
- mood disorders
- new
- ergolinas
- treatment methods
- methods
- Prior art date
Links
- 208000019022 Mood disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 abstract 2
- RHGUXDUPXYFCTE-ZWNOBZJWSA-N ergoline Chemical class C1=CC([C@@H]2[C@H](NCCC2)C2)=C3C2=CNC3=C1 RHGUXDUPXYFCTE-ZWNOBZJWSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179053P | 2021-04-23 | 2021-04-23 | |
| US202263308376P | 2022-02-09 | 2022-02-09 | |
| PCT/US2022/026186 WO2022226408A1 (en) | 2021-04-23 | 2022-04-25 | Novel ergolines and methods of treating mood disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021970A2 true BR112023021970A2 (pt) | 2023-12-26 |
Family
ID=81648213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021970A BR112023021970A2 (pt) | 2021-04-23 | 2022-04-25 | Novas ergolinas e métodos de tratamento de transtornos de humor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240368151A1 (https=) |
| EP (1) | EP4326718A1 (https=) |
| JP (1) | JP2024516174A (https=) |
| KR (1) | KR20240019091A (https=) |
| AU (1) | AU2022262659A1 (https=) |
| BR (1) | BR112023021970A2 (https=) |
| CA (1) | CA3223210A1 (https=) |
| IL (1) | IL307880A (https=) |
| MX (1) | MX2023012447A (https=) |
| WO (1) | WO2022226408A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230116703A1 (en) * | 2021-04-23 | 2023-04-13 | Gilgamesh Pharmaceuticals, Inc. | Novel ergolines and methods of treating mood disorders |
| CN117355302A (zh) | 2021-04-30 | 2024-01-05 | 思维医学股份有限公司 | Lsd盐晶体形式 |
| JP2024529727A (ja) | 2021-08-19 | 2024-08-08 | マインド メディシン， インコーポレイテッド | 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤 |
| JP2025525375A (ja) * | 2022-06-20 | 2025-08-05 | マインド メディシン， インコーポレイテッド | 修飾ｌｓｄ様作用を有するリゼルグ酸誘導体 |
| EP4630418B1 (en) * | 2022-12-31 | 2026-03-18 | Ceruvia Lifesciences LLC | Salts of 2-bromolysergic acid diethylamide |
| EP4704846A2 (en) * | 2023-05-04 | 2026-03-11 | Gilgamesh Pharmaceuticals, Inc. | Novel ergolines and methods of treating mood disorders |
| WO2025194238A1 (en) * | 2024-03-22 | 2025-09-25 | Blife Therapeutics Inc. | 2-bromo-lsd salts and polymorphs |
| WO2025235800A1 (en) | 2024-05-08 | 2025-11-13 | Cy Biopharma Ag | Ergoline derivatives and uses thereof |
| WO2025235784A2 (en) * | 2024-05-08 | 2025-11-13 | Cy Biopharma Ag | Ergoline derivatives and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2438259A (en) * | 1948-03-23 | D-lysergic acid diethyl amide | ||
| CN1087725C (zh) * | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| EP4219498A1 (en) * | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| US20230295106A1 (en) * | 2019-10-14 | 2023-09-21 | The Regents Of The University Of California | Ergoline-like compounds for promoting neural plasticity |
| EP4178956A2 (en) * | 2020-07-07 | 2023-05-17 | COMPASS Pathfinder Limited | Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof |
-
2022
- 2022-04-25 KR KR1020237040483A patent/KR20240019091A/ko active Pending
- 2022-04-25 EP EP22723308.7A patent/EP4326718A1/en active Pending
- 2022-04-25 IL IL307880A patent/IL307880A/en unknown
- 2022-04-25 BR BR112023021970A patent/BR112023021970A2/pt unknown
- 2022-04-25 JP JP2023564585A patent/JP2024516174A/ja active Pending
- 2022-04-25 WO PCT/US2022/026186 patent/WO2022226408A1/en not_active Ceased
- 2022-04-25 US US18/287,980 patent/US20240368151A1/en active Pending
- 2022-04-25 AU AU2022262659A patent/AU2022262659A1/en active Pending
- 2022-04-25 MX MX2023012447A patent/MX2023012447A/es unknown
- 2022-04-25 CA CA3223210A patent/CA3223210A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL307880A (en) | 2023-12-01 |
| AU2022262659A1 (en) | 2023-10-19 |
| US20240368151A1 (en) | 2024-11-07 |
| EP4326718A1 (en) | 2024-02-28 |
| WO2022226408A1 (en) | 2022-10-27 |
| CA3223210A1 (en) | 2022-12-27 |
| JP2024516174A (ja) | 2024-04-12 |
| KR20240019091A (ko) | 2024-02-14 |
| MX2023012447A (es) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023021970A2 (pt) | Novas ergolinas e métodos de tratamento de transtornos de humor | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| JOP20230277A1 (ar) | مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض | |
| CY1126103T1 (el) | ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΚΑΙ ΦΑΡΜΑΚΟΤΕΧΝΙΚΕΣ ΜΟΡΦΕΣ ΤΟΥ(S)-4-(8-AMINO-3-(l-(BOYT-2-YNOΫΛO)ΠYPPOΛΙΔΙΝ-2-YΛO)ΙΜΙΔΑΖΟ[1,5-Α]ΠΥΡΑΖΙΝ-1-ΥΛΟ)-Ν-(ΠΥΡΙΔΙΝ-2-ΥΛΟ)ΒΕΝΖΑΜΙΔΙΟΥ | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| BR112015026380A8 (pt) | esteróides de c21-n-pirazolil 19-nor c3,3-dissubstituídos e métodos de uso destes | |
| MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
| CO2018010966A2 (es) | Nuevos derivados de pirazolopirimidina | |
| MX387784B (es) | Composiciones novedosas y metodos. | |
| WO2024091506A3 (en) | Novel ergolines and methods of treating mood disorders | |
| CR20220064A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| BR112017007708A2 (pt) | composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente | |
| ECSP20077106A (es) | Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k | |
| CO2023010694A2 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| JOP20230170A1 (ar) | مثبطات cdk2 وطرق لاستخدامها | |
| BR112023018237A2 (pt) | Fenalquilaminas e métodos para fabricação e uso das mesmas | |
| CO2022000422A2 (es) | Inhibidores de enzimas | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| DOP2025000213A (es) | [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4 | |
| MX2025013117A (es) | Ergolinas novedosas y métodos de tratamiento de trastornos del estado de ánimo | |
| EP3604304A4 (en) | COMPOUND DERIVED FROM PYRROLO-PYRIDINE, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT AS AN ACTIVE PRINCIPLE FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH KINASE PROTEIN | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| MX2024012625A (es) | Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos | |
| DOP2022000127A (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos. | |
| MX2023015097A (es) | Tratamiento de sintomas asociados a neoplasias mieloproliferativas. |